←
Christopher Garris1,679 posts
Christopher Garris avatar

Christopher Garris

@csgarrix

Assistant Professor Mass General @MGHCSB @MGHPathology and Harvard Med @harvardmed specializing in Immuno-Oncology with a focus on Dendritic Cells.

◷ Joined November 2013▧ 28 Photos and videos
Juan C Osorio MD avatar
⟳ Christopher Garris retweeted
Juan C Osorio MD@juanosoriomd·19h

Excited to share our study, published today in @CCR_AACR Can we harness CD40 agonism to treat bladder cancer? And how spatial immune organization within tumors correlate with response? We report findings from a phase I trial of our Fc-engineered CD40 agonist. 🧵🪡 link 👇

Jonathan Kagan avatar
⟳ Christopher Garris retweeted
Jonathan Kagan@jkagan1·Nov 11

The NRF2-KEAP1 regulon is a transcriptional checkpoint for the NLRP3 inflammasome. Very pleased to share our study on how NRF2-KEAP1 links extracellular matrix sensing to NLRP3 regulation. Links to fibrosis, inflammation and cancer are presented. nature.com/articles/s41586-0…

Semir Beyaz avatar
⟳ Christopher Garris retweeted
Semir Beyaz@beyazlab·Oct 18

Our new paper in @NatImmunol explores this question through PPARδ, a lipid-sensing transcription factor that we identify as a regulator of the #fitness balance between #cancer and #immune cells. You can read the open access paper here: nature.com/articles/s41590-0…

Christopher Garris avatar
Christopher Garris@csgarrix·Aug 21

Fantastic study. With the recent resurgence in cancer vaccines, we should also consider that communication with cDC1 could be critical for response. Ken’s recent paper even shows potential long-term deficiencies in CD8 T cells activated through dressed cDC2. cDC1 remains king. 👑

1/15 academic.oup.com/jimmunol/ar… New study from a collaboration between the Gubin lab and @swatowic Watowich lab and led by Josué Pineda and Tomoyuki Minowa. Long read, I know. Type 1 conventional dendritic cells (DC1s) play a central role in coordinating antitumor immunity, yet

Matthew Gubin avatar
⟳ Christopher Garris retweeted
Matthew Gubin@GubinMatthew·Aug 20

1/15 academic.oup.com/jimmunol/ar… New study from a collaboration between the Gubin lab and @swatowic Watowich lab and led by Josué Pineda and Tomoyuki Minowa. Long read, I know. Type 1 conventional dendritic cells (DC1s) play a central role in coordinating antitumor immunity, yet

Nikita Bier avatar
⟳ Christopher Garris retweeted
Nikita Bier@nikitabier·Aug 19

With cancer vaccines now being discovered with AI ($MRNA), it seems that the US government might actually grow its way out of its budget deficit. It feels like we're in the early innings of the healthcare system becoming unburdened by many terminal illnesses.

Banana Oncology avatar
⟳ Christopher Garris retweeted
Banana Oncology@Banana_Oncology·Aug 19

Huge congrats to $MRK and $MRNA! The entire personalized cancer vaccine platform is now de-risked, many more cancer types to come Now it's interesting to see what that means for $PSNL, the sole company helping $MRK and $MRNA to sequence these tumors and design these neoantigrn vaccines

🚨🚨🚨BREAKING CANCER NEWS! 🚨🚨🚨 Merck $MRK and Moderna $MRNA personalized mRNA cancer vaccine slowed the return of melanoma and its spread to other parts of the body in a Ph3 clinical trial. No data disclosed yet, but the study was stopped for positive results at the first interim analysis. Magnitude of benefit TBD, but this is a potentially huge breakthrough for cancer patients and the use of mRNA to treat cancer. Read STAT's story from @matthewherper and @angRchen statnews.com/2026/08/19/mrna…

Adam Feuerstein ✡️ avatar
⟳ Christopher Garris retweeted
Adam Feuerstein ✡️@adamfeuerstein·Aug 19

🚨🚨🚨BREAKING CANCER NEWS! 🚨🚨🚨 Merck $MRK and Moderna $MRNA personalized mRNA cancer vaccine slowed the return of melanoma and its spread to other parts of the body in a Ph3 clinical trial. No data disclosed yet, but the study was stopped for positive results at the first interim analysis. Magnitude of benefit TBD, but this is a potentially huge breakthrough for cancer patients and the use of mRNA to treat cancer. Read STAT's story from @matthewherper and @angRchen statnews.com/2026/08/19/mrna…

Rony Dahan avatar
⟳ Christopher Garris retweeted
Rony Dahan@DahanLab·Aug 5

1/ Why have anti-GITR agonists, despite strong preclinical activity, shown limited clinical success? Our new study in @NatureCancer points to Fc receptor pathways as a key missing piece. Led by the amazing @AvYahel, Natasha Barth nature.com/articles/s43018-0…

Cell Reports Medicine avatar
⟳ Christopher Garris retweeted
Cell Reports Medicine@CellRepMed·Aug 1

Online now: Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer dlvr.it/TTplgV

Dr. Bishoy M. Faltas avatar
⟳ Christopher Garris retweeted
Dr. Bishoy M. Faltas@FaltasLab·Aug 1

Thank you to @CBSNews for highlighting our #research! For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit. Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer. This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab

What if doctors could test cancer treatments on your tumor, without putting a single one of those treatments into your body? CBS News’ Riley Callanan reports.

2:01
Christopher Garris avatar
Christopher Garris@csgarrix·Jul 30

Sigh… another “finalist” level proposal waitlisted again and likely won’t be funded. This keeps on happening and oddly, I’d prefer the hard reject as opposed to the repeated near misses; that way I wouldn’t keep wasting time and have more reason to course correct.